Using botulinum toxin to treat diabetic foot pain

Neurology

Volumn 72, Issue 17, 2009, Pages

  Kaufman, Jacob L ^a   Karceski, Steven ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BOTULINUM TOXIN A; DULOXETINE; HEMOGLOBIN A1C; MORPHINE; OPIATE; PLACEBO; PREGABALIN; NEUROTOXIN;

CLINICAL FEATURE; DIABETIC FOOT; DIABETIC NEUROPATHY; FOOT PAIN; HUMAN; NERVE CONDUCTION; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; TREATMENT RESPONSE; VISUAL ANALOG SCALE; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FOOT; HYPERGLYCEMIA; INNERVATION; METHODOLOGY; PAIN ASSESSMENT; PATHOLOGY; PATHOPHYSIOLOGY; PATIENT EDUCATION; SENSORY RECEPTOR; STATISTICS; TREATMENT OUTCOME;

BOTULINUM TOXIN TYPE A; CLINICAL TRIALS AS TOPIC; DIABETIC NEUROPATHIES; FOOT; HUMANS; HYPERGLYCEMIA; NEUROTOXINS; PAIN MEASUREMENT; SENSORY RECEPTOR CELLS; TREATMENT OUTCOME;

EID: 67549147146     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181a669ff     Document Type: Article

References (4)

1. Yuan R-Y, Sheu J-J, Yu J-M, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009;72:1473-1478.
2. Apfel SC. Botulinum toxin for neuropathic pain? Neurology 2009;72:1456 -1457.
3. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA 2003;290:1884- 1890.
4. Amthor KF, Dahl-Jørgensen K, Berg TJ, et al. The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients: the Oslo Study. Diabetologia 1994;37:579-584.